Market Place
Sourcing Support
MacroGenics to Participate in Upcoming Investor Conference
02 Dec 2024 //
GLOBENEWSWIRE
MacroGenics to Participate in Upcoming Investor Conferences
06 Nov 2024 //
GLOBENEWSWIRE
MacroGenics pauses work on ADC pending mature survival data
06 Nov 2024 //
FIERCE BIOTECH
MacroGenics Updates on Corporate & Q3 2024 Financial Results
05 Nov 2024 //
GLOBENEWSWIRE
MacroGenics Announces Leadership Transition
30 Oct 2024 //
GLOBENEWSWIRE
MacroGenics Announces Q3 2024 Results Conference Call Date
29 Oct 2024 //
GLOBENEWSWIRE
MacroGenics Enters Agreement With TerSera For MARGENZA®
22 Oct 2024 //
BUSINESSWIRE
TerSera picks up MacroGenics` Margenza for $40M plus milestones
22 Oct 2024 //
FIERCE PHARMA
MacroGenics Shares TAMARACK Study Data On Vobra Duo In mCRPC At ESMO
15 Sep 2024 //
GLOBENEWSWIRE
MacroGenics Announces TAMARACK Phase 2 Data Presentation at ESMO Congress 2024
08 Sep 2024 //
GLOBENEWSWIRE
MacroGenics Provides Corporate Progress And Q2 2024 Results
06 Aug 2024 //
GLOBENEWSWIRE
MacroGenics Achieves $100M Milestone In Incyte Collaboration
30 Jul 2024 //
GLOBENEWSWIRE
MacroGenics Provides Vobramitamab Duocarmazine Update
30 Jul 2024 //
GLOBENEWSWIRE
MacroGenics to Participate in Upcoming Investor Conference
11 Jun 2024 //
GLOBENEWSWIRE
MacroGenics to Participate in Upcoming Investor Conferences
13 May 2024 //
GLOBENEWSWIRE
MacroGenics` stock crashes after 5 deaths in ADC trial
11 May 2024 //
FIERCE PHARMA
MacroGenics Corporate Progress, Q1 2024 Results, TAMARACK Data
09 May 2024 //
GLOBENEWSWIRE
MacroGenics Announces Date of First Quarter 2024 Financial Results
03 May 2024 //
GLOBENEWSWIRE
MacroGenics Provides Ph 2 TAMARACK Study Early Interim Safety Data
03 Apr 2024 //
GLOBENEWSWIRE
AbbVie drops MacroGenics-partnered ADC in light of early data
09 Mar 2024 //
FIERCE BIOTECH
MacroGenics Provides Update on Corporate Progress and 2023 Financial Results
07 Mar 2024 //
GLOBENEWSWIRE
MacroGenics to Participate in Upcoming Investor Conferences
01 Mar 2024 //
GLOBENEWSWIRE
MacroGenics Announces Date of Q4 2023 Financial Results Conference Call
27 Feb 2024 //
GLOBENEWSWIRE
MacroGenics to Participate in Upcoming Investor Conference
02 Feb 2024 //
GLOBENEWSWIRE
MacroGenics to Participate in Upcoming Investor Conference
08 Jan 2024 //
GLOBENEWSWIRE
MacroGenics Provides Third Quarter 2023 Financial Results
06 Nov 2023 //
GLOBENEWSWIRE
MacroGenics to Participate in Upcoming Investor Conferences
02 Nov 2023 //
GLOBENEWSWIRE
MacroGenics Announces Date of Third Quarter 2023 Financial Results Conference
31 Oct 2023 //
GLOBENEWSWIRE
MacroGenics to Participate in Upcoming Investor Conferences
31 Aug 2023 //
GLOBENEWSWIRE
MacroGenics Provides Second Quarter 2023 Financial Results
09 Aug 2023 //
GLOBENEWSWIRE
MacroGenics Announces Date of Q2 2023 Financial Results Conference Call
31 Jul 2023 //
GLOBENEWSWIRE
MacroGenics Provides Update on Corporate Progress and1Q 2023 FYR
09 May 2023 //
GLOBENEWSWIRE
MacroGenics Announces Date of 1Q FYR 2023 Conference Call
04 May 2023 //
GLOBENEWSWIRE
MacroGenics to Participate in Upcoming Investor Conferences
24 Apr 2023 //
GLOBENEWSWIRE
MacroGenics Earns $15 Million Milestone Following U.S. FDA Approval of ZYNYZ
22 Mar 2023 //
GLOBENEWSWIRE
MacroGenics Provides Corporate Update and 2022 Financial Results
15 Mar 2023 //
GLOBENEWSWIRE
Synaffix, MacroGenics crack open ADC pact, tack on $2.2B to deal
15 Mar 2023 //
FIERCE BIOTECH
MacroGenics Announces Date of Fourth Quarter 2022 Financial Results Conference
07 Mar 2023 //
GLOBENEWSWIRE
MacroGenics to Participate in Upcoming Investor Conferences
02 Mar 2023 //
GLOBENEWSWIRE
MacroGenics Announces Preliminary Results from Single Arm Study of Lorigerlimab
13 Feb 2023 //
GLOBENEWSWIRE
MacroGenics to Participate in Upcoming Investor Conferences
06 Feb 2023 //
GLOBENEWSWIRE
MacroGenics Appoints Margaret Liu & Meenu Chhabra Karson to Board of Directors
04 Jan 2023 //
GLOBENEWSWIRE
MacroGenics to Present at the 41st Annual J.P. Morgan Healthcare Conference
04 Jan 2023 //
GLOBENEWSWIRE
MacroGenics Earns $60 Million Milestone with U.S. FDA Approval of Teplizumab
17 Nov 2022 //
PRESS RELEASE
Why MacroGenics Stock Popped Again Today
07 Nov 2022 //
FOOL
MacroGenics Provides Corporate Update and Third Quarter 2022 Financial Results
03 Nov 2022 //
GLOBENEWSWIRE
MacroGenics to Participate in Upcoming Investor Conferences
02 Nov 2022 //
PRESS RELEASE
MacroGenics Announces Date of Third Quarter 2022 Financial Results Conference
26 Oct 2022 //
GLOBENEWSWIRE
Gilead offers $1.76B for option to MacroGenics` bispecific
18 Oct 2022 //
FIERCEBIOTECH
MacroGenics joins biotech layoff wave, slashing 15% of workers
09 Aug 2022 //
FIERCEBIOTECH
MacroGenics Reports Second Quarter 2022 Financial Results
08 Aug 2022 //
GLOBENEWSWIRE
MacroGenics Announces Date of Q2 2022 Financial Results Conference Call
25 Jul 2022 //
GLOBENEWSWIRE
MacroGenics closes solid tumor clinical trial after 7 people die
12 Jul 2022 //
FIERCEBIOTECH
MacroGenics Announces Closure of CP-MGA271-06 Study Evaluating Enoblituzumab
08 Jul 2022 //
GLOBENEWSWIRE
MacroGenics Announces Appointment of William Heiden to Board of Directors
23 May 2022 //
GLOBENEWSWIRE
MacroGenics to Participate in Upcoming Investor Conference
17 May 2022 //
GLOBENEWSWIRE
Why MacroGenics Stock Is Tanking Today
04 May 2022 //
FOOL
MacroGenics plans to start a PhII/III by year`s end — once they raise the cash
04 May 2022 //
ENDPTS
MacroGenics Provides Update on Corporate Progress and Q1 2022 Financial Results
03 May 2022 //
GLOBENEWSWIRE
MacroGenics Announces Date of First Quarter 2022 Financial Result
25 Apr 2022 //
GLOBENEWSWIRE
